Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

224 trials with published results (20%)

Research Maturity

813 completed trials (72% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.7%

65 terminated out of 1136 trials

Success Rate

92.6%

+6.0% vs benchmark

Late-Stage Pipeline

17%

189 trials in Phase 3/4

Results Transparency

28%

224 of 813 completed with results

Key Signals

224 with results93% success65 terminated

Data Visualizations

Phase Distribution

894Total
Not Applicable (398)
Early P 1 (7)
P 1 (172)
P 2 (128)
P 3 (126)
P 4 (63)

Trial Status

Completed813
Unknown104
Recruiting79
Terminated65
Active Not Recruiting33
Withdrawn23

Trial Success Rate

92.6%

Benchmark: 86.6%

Based on 813 completed trials

Clinical Trials (1136)

Showing 20 of 20 trials
NCT07087795Phase 1Active Not RecruitingPrimary

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

NCT06422494Not ApplicableCompletedPrimary

The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II

NCT05478707Phase 2RecruitingPrimary

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

NCT06329375Not ApplicableRecruiting

Food Insecurity Reduction & Strategy Team

NCT05428943Phase 1CompletedPrimary

OPT101 in Type 1 Diabetes Patients

NCT07222137Phase 3RecruitingPrimary

A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

NCT07222332Phase 3RecruitingPrimary

A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

NCT07745998Not ApplicableNot Yet RecruitingPrimary

The BRIGHT Study (Device Name: HALO System)

NCT06046833Not ApplicableRecruiting

Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes

NCT06238778Phase 2CompletedPrimary

Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec

NCT06334133Phase 3Active Not RecruitingPrimary

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

NCT06236256Not ApplicableCompletedPrimary

Advanced Hybrid Closed Loop System (AHCL) in Older Patients With Type 1 Diabetes Mellitus

NCT05849753RecruitingPrimary

Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes

NCT07711275Not ApplicableCompletedPrimary

Hypoglycemia Thresholds in Type 1 Diabetes

NCT06688331Phase 2Recruiting

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

NCT03938324Not ApplicableCompleted

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT06880835Not ApplicableRecruitingPrimary

Effect of Inhaled Technosphere Insulin vs RAA Insulin on Exercise-Induced Hypoglycemia in Adults With T1D Using Automated Insulin Delivery

NCT07090824Phase 1CompletedPrimary

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT04786262Phase 3RecruitingPrimary

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

NCT05756361Not ApplicableCompletedPrimary

Family-Based Treatment for Type 1 Diabetes

Scroll to load more

Research Network

Activity Timeline